Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
Location: United States, California, Los Angeles
Employees: 11-50
Total raised: $52M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 12.05.2021 | Two Sigma ... | twosigmave... |
| - | Freeflow V... | freeflow.i... |
| - | Axial VC | axialvc.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2021 | Series A | $52M | Two Sigma ... |
Mentions in press and media 7
| Date | Title | Description |
| 14.01.2022 | Our 2021 Predictions Report Card: How Accurate Were We? | Each year we pause to reflect on what happened in the tech and VC space and share new predictions for the coming year. Last year, we shared 10 forecasts and tech trends that we expected to see in 2021, and now we’re looking back and judging... |
| 12.08.2021 | Appia Bio Inks Mega Deal To Scale Cancer Therapies | The next wave of cancer treatments uses the body's own immune system rather than chemotherapy or radiation to kill cancer cells. Treatments are being developed by two Southern California pharma companies. Last week, one of the biggest playe... |
| 21.05.2021 | Appia Bio Raises $52M in Series A Financing | Appia Bio, Inc., a Los Angeles, CA-based early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, launched from stealth with $52m in Series A financing. The ... |
| 11.05.2021 | Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board | |
| 11.05.2021 | Appia Bio : Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board | LOS ANGELES, May 11, 2021 /PRNewswire/ -- Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced its launch from stealt... |
| 11.05.2021 | Appia Bio Takes $52M For Stem Cell Therapy | Los Angeles-based Appia Bio, a biotech startup focused on developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, has launched from stealth mode, saying it has raised $52M in a Series A fund... |
| 11.05.2021 | Appia Bio Comes Out of Stealth Aiming to Offer Faster, Safer Cancer-Fighting Therapies | Cell therapy has taken the oncology world by storm. For cancer patients who have tried every other treatment, cell therapies not only have the potential to kill cancer cells in the moment, but they can multiply and continue bolstering the i... |